Ilonov develops first-in-class biotherapies unlocking the muscle secretome to counter metabolic dysfunction. Our lead assets, based on human-centric discovery, preserve mitochondrial health, maintain tissue function and reduce chronic inflammation, addressing the unmet need in diabetes and MASH.

Enabling breakthrough medicines achieve the outcomes they were designed for. We unlock the full therapeutic potential of innovative drug candidates through our next-gen nanomedicine delivery platform. We want to establish our biovectors as the universal standard for targeted therapeutic delivery.

RhyGaze is a cutting-edge biotechnology company based in Basel, Switzerland, and Philadelphia, Pa., USA, focused on developing gene therapies for retinal diseases causing blindness and aims to restore vision and transform the lives of patients worldwide.